Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ALX Oncology Holdings Inc. (ALXO)

4.52   -0.04 (-0.88%) 03-31 16:00
Open: 4.58 Pre. Close: 4.56
High: 4.69 Low: 4.4925
Volume: 168,399 Market Cap: 185(M)

Technical analysis

as of: 2023-03-31 4:16:40 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.96     One year: 8.05
Support: Support1: 4.44    Support2: 3.69
Resistance: Resistance1: 5.96    Resistance2: 6.9
Pivot: 4.9
Moving Average: MA(5): 4.78     MA(20): 5.19
MA(100): 8.91     MA(250): 10.18
MACD: MACD(12,26): -0.7     Signal(9): -0.8
Stochastic oscillator: %K(14,3): 13.1     %D(3): 17.7
RSI: RSI(14): 28.1
52-week: High: 19.22  Low: 4.44
Average Vol(K): 3-Month: 233 (K)  10-Days: 318 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALXO ] has closed above bottom band by 16.3%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.18 - 5.21 5.21 - 5.23
Low: 4.38 - 4.41 4.41 - 4.43
Close: 4.52 - 4.56 4.56 - 4.6

Company Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Headline News

Tue, 14 Mar 2023
ALX Oncology and Quantum Leap Healthcare CollaborativeTM ... - PR Newswire

Mon, 13 Mar 2023
HC Wainwright reduced ALX Oncology (NASDAQ:ALXO) PT to $30.00. - Best Stocks

Fri, 10 Mar 2023
Bay Area biotechs seek to assure investors of minimal SVB ... - The Business Journals

Thu, 09 Mar 2023
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones - Yahoo Finance

Thu, 16 Feb 2023
ALX Oncology Announces First Patient Dosed in ASPEN-07, a ... - GlobeNewswire

Thu, 05 Jan 2023
ALX Oncology Provides Corporate Update and Highlights Key ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 41 (M)
Shares Float 16 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 101.6 (%)
Shares Short 3,840 (K)
Shares Short P.Month 3,870 (K)

Stock Financials

EPS -2.58
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.44
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -23.3
Return on Equity (ttm) -39.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.12
Qtrly Earnings Growth 0
Operating Cash Flow -89 (M)
Levered Free Cash Flow -93 (M)

Stock Valuations

PE Ratio -1.76
PEG Ratio 0
Price to Book value 0.7
Price to Sales 0
Price to Cash Flow -2.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.